5th TCR-based Therapies for Solid Tumors Summit 2024 Hilton Boston Back Bay, Boston

Our core commitment centers on advancing R and D and Clinical Development strategies for TCR therapies, aiming to harness their immense potential in targeting solid tumors. These therapies offer promising avenues for enhancing treatment methodologies, thereby fostering optimism for improved outcomes among patients grappling with these challenging conditions.

The recent submission of a Biologics License Application (BLA) by Adaptimmune is a remarkable milestone, signifying remarkable progress in gaining regulatory approval for their TCR-based cancer therapy. This achievement indicates a pivotal step forward, paving the way for broader accessibility of this innovative treatment to patients in critical need.

The 5th TCR-based Therapies for Solid Tumors Summit returns as your only meeting where TCR pipelines have the center stage, serving as your ultimate platform to network with the most senior industry leaders in biopharma dedicated to accelerating clinical and commercial development of TCR-based therapeutics.